Amarin Corp Plc (AMRN)

[Biobillionair]

'598 aplication is '146 patent. Listed in the OB here:
http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=202057&Product_No=001&table1=OB_Rx

'146 claims: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.

The invention claimed is:

1. A pharmaceutical composition comprising one or more fatty acids, at least 95% of which are in the form of ethyl-eicosapentaenoic acid, wherein the composition contains no docosahexaenoic acid and the composition is present in a capsule.

2. The composition of claim 1 wherein the composition contains less than 3% of any fatty acid other than eicosapentaenoic acid.

3. The composition of claim 2 wherein the capsule is a gelatin capsule.

4. The composition of any one of claim 1, 2, or 3 wherein the ethyl-eicosapentaenoic acid is present in the composition in an amount of 250 mg to 1000 mg.

5. A pharmaceutical composition comprising 250 mg to 1000 mg of fatty acids at least 95% of which are in the form of ethyl eicosapentaenoic acid, wherein the composition contains no docosahexaenoic acid, and the composition is present in a capsule.

6. A pharmaceutical composition comprising 250 mg to 1000 mg of fatty acids at least 95% of which are in the form of ethyl-eicosapentaenoic acid, wherein the composition contains (a) less than 5% in aggregate of arachidonic acid and n-3 docosapentaenoic acid, and (b) no docosahexaenoic acid; and wherein the composition is present in a capsule.

7. The pharmaceutical composition of claim 5 wherein the composition contains arachidonic acid in an amount less than 3%, by weight, of said fatty acids.

8. The pharmaceutical composition of claim 6 wherein the composition contains docosapentaenoic acid in an amount less than 3%, by weight, of said fatty acids.

9. The pharmaceutical composition of claim 6 wherein the composition contains arachidonic acid and docosapentaenoic acid in an aggregate amount of less than 3%, by weight, of said fatty acids.

10. The pharmaceutical composition of claim 6 wherein the capsule comprises about 1000 mg of said composition.
--------------------------

Very important points AZN:
1) Amarin has it in the OB, "Fatty Acid"
2) Claim #8 shoots your Omthera Patent app #13734846 DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM

I was slightly concerned you might have got that one through, until today. Epanova's got a snowballs-in-hell for getting IP or NCE. If it makes it beyond the 74 day letter, which I doubt due to Lovaza RLD.

What a waste of $260 Million!

Biobill